Siga Technologies (SIGA) Income from Continuing Operations (2010 - 2025)
Siga Technologies (SIGA) posted Income from Continuing Operations of 6365819.0 for Q3 2025, down 117.94% on a QoQ basis from 35483103.0 in Q2 2025, and down 573.67% year-over-year from 1343945.0 in Q3 2024.
Siga Technologies (SIGA) Income from Continuing Operations (2010 - 2025) Analysis & Trends
Siga Technologies' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 6365819.0 for Q3 2025.
- Quarterly Income from Continuing Operations fell 573.67% year-over-year to 6365819.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 74628430.0 (down 7.78% YoY) and the FY2024 annual result came in at 59407632.0, down 6.11% from the prior year.
- Income from Continuing Operations was 6365819.0 for Q3 2025 at Siga Technologies, down from 35483103.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 73212356.0 in Q4 2021 and bottomed at 6365819.0 in Q3 2025.
- A 5-year average of 13404891.16 and a median of 169200.0 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations soared 8410.3% — and 2025, when it plunged 573.67%.
- Siga Technologies' Income from Continuing Operations stood at 73212356.0 in 2021, then plunged by 101.11% to 811794.0 in 2022, then surged by 8410.3% to 67462530.0 in 2023, then sank by 31.93% to 45919369.0 in 2024, then plunged by 113.86% to 6365819.0 in 2025.
- Business Quant data shows SIGA's Income from Continuing Operations at 6365819.0 in Q3 2025, 35483103.0 in Q2 2025, and 408223.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Siga Technologies | 225.56 Mn | 70.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -6.37 Mn |
| Jun 30, 2025 | 35.48 Mn |
| Mar 31, 2025 | -408,223.00 |
| Dec 31, 2024 | 45.92 Mn |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 10.32 Mn |
| Dec 31, 2023 | 67.46 Mn |
| Sep 30, 2023 | -393,066.00 |
| Jun 30, 2023 | -2.85 Mn |
| Mar 31, 2023 | -917,677.00 |
| Dec 31, 2022 | -811,794.00 |
| Sep 30, 2022 | 33.03 Mn |
| Jun 30, 2022 | 1.99 Mn |
| Mar 31, 2022 | -364,455.00 |
| Dec 31, 2021 | 73.21 Mn |
| Sep 30, 2021 | -3.08 Mn |
| Jun 30, 2021 | 169,200.00 |
| Mar 31, 2021 | -845,038.00 |
| Dec 31, 2020 | 20.16 Mn |